SmartPeptide
Start Free
CognitiveLimited human evidence

Selank

Synthetic analog of a fragment of human tuftsin, studied in Russia for anxiolytic and nootropic effects.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Russian clinical work suggests anxiolytic effects without sedation. Some EEG and BDNF-related findings.

What's still experimental

Independent western replication is limited. Mechanisms beyond GABAergic modulation are speculative.

Anecdotal / community reports

Reports of acute anxiety relief and improved focus are common online; effect sizes vary.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “Selank”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

Source: Published clinical trial

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

Community-anecdotal range — NOT a SmartPeptide recommendation

The doses below are aggregated from research-peptide community forums (Reddit, biohacker discussions). They are NOT supported by clinical trials, NOT FDA-approved, and NOT a SmartPeptide recommendation. Source purity, dose accuracy, and user-reported outcomes are unverifiable. We display this only because the information is publicly available elsewhere — visitors should absolutely consult a licensed clinician familiar with experimental peptides before any use.

Community-anecdotal — not evidence-basedRussian clinical literature + nootropic forums
Indication studied: Community-discussed for anxiolytic effect (some Russian human trials)
Typical
250µg
2-3x daily · intranasal

Russian trial doses commonly cited

Open calculator
Maximum
500µg
2-3x daily · intranasal

Higher community range

Open calculator

Notes from the source: Russian Phase 2-style studies report anxiolytic effects but have not been replicated in Western RCTs.

Important framing: The numbers above are what published trials tested or what FDA-approved labels specify. They are NOT a SmartPeptide recommendation for you. Trial doses come paired with screening, monitoring, and clinician oversight. Always consult a licensed clinician before any peptide use.

How clinicians typically protocol this

Third-party reference · not our recommendation

Dosing phases, cycle lengths, and administration timing as listed in a compounding-pharmacy clinician reference guide. Shown so you can see what a real protocol looks like — and bring informed questions to a licensed clinician.

Third-party protocol referenceCompounding-pharmacy clinician protocol reference (Nov 2025)

Dose numbers, frequencies, and cycle lengths in this panel are extracted from a clinician-facing reference protocol distributed by a US-based compounding pharmacy in November 2025. SmartPeptide has paraphrased all descriptive text and adds no endorsement. Always consult a licensed clinician.

Nootropic

Synthetic Tuftsin-derived heptapeptide studied for anxiolytic and cognitive effects.

Protocol phases

Anxiolytic
400 µg – 1 mgdaily, split AM + early afternoon
subcutaneous or intranasal
Cognitive
200–400 µgdaily, split
subcutaneous or intranasal
Maximum
2 mgper week
subcutaneous or intranasal
Cycle length

4–6 week cycles with 2-week breaks to reset sensitivity.

Administration timing

Rapid onset (15–30 min intranasal); half-life ~2–4 hr.

Protocol notes: Often stacked with Semax (focus) or Thymosin Alpha-1 (immune) per this reference.

Reconstitution calculator Storage & reconstitution guide
Not medical advice. SmartPeptide does not prescribe, diagnose, or treat. The protocol above reproduces dose figures from a third-party clinician reference so you can see what compounding-pharmacy guidance typically looks like — it is not a recommendation for you, and it has not been validated against peer-reviewed dose-ranging trials. Many of these compounds are not FDA-approved for human use. Work with a licensed clinician familiar with peptide therapy before considering anything here.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “Selank”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets
No mechanism data indexed in ChEMBL, UniProt, or Open Targets for “Selank”. This is common for unscheduled research peptides that haven't been studied in structured target-binding assays.

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
136
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
10 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "selank"

Europe PMC — 81 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
278
all years
Last 5 years
114
recent activity
Open access
169
freely readable
OA share
61%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “selank” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
81
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • Russian Foundation for Basic Research2 works
  • Russian Science Foundation1 works
  • Russian Academy of Sciences programs: “Molecular and Cellular Biology”, “Basic Sciences for Medicine”, “Mechanisms of Integration of Molecular Systems in the Implementation of the Physiological Functions”1 works
  • Leading Scientific Schools1 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC
No preprints indexed yet for “selank”.

Known risks

Most data is from a single national research tradition; independent replication is limited.

Reported side effects

Reported as mild in available studies.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “Selank”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Not FDA-approved. Discuss with a clinician — especially if you take other anxiolytics or antidepressants.

Questions for your clinician

  • What independent (non-Russian) human evidence exists?
  • Could this interact with SSRIs/SNRIs/benzodiazepines?

Editorially curated references

Discussions about Selank

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all Selank discussions Native, moderated, no buying or selling